Table 1.
Highlighted studies on taurine implications for beneficial effects to CVD.
| Ref. | Subject | Dose/Time | Outcome |
|---|---|---|---|
| [205,207] | Heart Failure | 1500 mg/day, 2 weeks | Improved exercise capacity, reduced TC/HDL-c, and reduced hsCRP |
| [208] | Chronic Heart Failure | 3000 mg/day, 30–45 days | Decreased left ventricular end-diastolic volume with left ventricular dysfunction before revascularization |
| [209] | Chronic Heart Failure | 3000 mg/day, 6 weeks | Improvement in systolic left ventricular function |
| [19] | Cardiomyopathy | 100 mg/day, 24 months | Restored taurine concentration and corrected left ventricular dysfunction |
| [212] | Stage 1 hypertension | 1600 mg/day, 12 weeks | Improved vasodilation and reduced blood pressure |
| [213] | Hypertension | 6000 mg/day, 7 days | Reduced blood pressure |
| [214] | VascularDysfunction induced by CBS deficiency | 5000 mg/day, 6 days | Improved vasodilation |
| [215] | Type-2 diabetes with vascular dysfunction | 1500 mg/day, 2 weeks | Reversed vascular dysfunction |
| [216] | Type-2 diabetes | 1500 mg/day, 90 days | Decreased platelet aggregation |
| [218] | Type-2 diabetes | 3000 mg/day, 8 weeks | Decreased FBS, triglycerides, and LDL-c |
| [220] | Type-2 diabetes | 3000 mg/day, 8 weeks | Increased SOD and decreased hsCRP, TNF-α, and IL-6 |
CBS, cystathionine β synthase deficiency; FBS, fasting blood sugar; HDL-c, high-density lipid cholesterol; hsCRP, high-sensitivity C-reactive protein; LDL-c, low-density lipid cholesterol; TC, total cholesterol.